BioSpace News Archive

YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”) today announced that the United States Patent and Trademark Office has issued it a patent covering the Company’s PIKA YS-HBV-002, an immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus (“HBV”) infection.

Therapeutic Solutions International, Inc. (TSOI) announced today new data and a patent filing from its Subsidiary Company Res Nova Bio which, according to Company scientists, is a potential breakthrough in the field of immunotherapy of cancer.

Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) and Sumitomo Pharma Switzerland GmbH (‘SMPS’) today announce that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO®.

A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries.

Nephron Pharmaceuticals Corporation celebrated a successful $350 million capital raise – led by BlackRock Capital Investment Advisors, LLC and PNC Bank, National Association – to support future growth of the pharmaceutical manufacturer.

United Urology Group and its Affiliate Practices and Prostate Centers USA® are pleased to announce a groundbreaking initiative in the treatment of Benign Prostatic Hyperplasia.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 8,750 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 5,000 shares of common stock and inducement restricted stock units, covering an aggregate of 3,750 shares of its common stock.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, reported its financial results for the half-year ended June 30, 2023 and provided a corporate update.

PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy.

Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, announced today that members of its executive leadership team will participate at two upcoming investor conferences.